Prescription medicine
Fremanezumab Brand names: Ajovy
Fremanezumab (Ajovy) is a prescription medicine. No generic is listed; pharmacies paid $508.17 per mL (Ajovy 225 mg/1.5 mL autoinject) in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the fremanezumab FDA label on DailyMed (effective June 5, 2026); every fremanezumab label on DailyMed.
Highlights of the record
FDA label of June 5, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageAJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Forms and strengths
- 225 mg/1.5ml
Injection.
On the market
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $508.17 per mL Ajovy 225 mg/1.5 mL autoinject
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 11,413 through July 30, 2026
What is fremanezumab used for?
From the label: indications and usageAJOVY is indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more. AJOVY is a calcitonin gene-related peptide antagonist indicated for: the preventive treatment of migraine in adults, and the preventive treatment of episodic migraine in pediatric patients who are 6 to 17 years of age and who weigh 45 kg or more.
Conditions named in the indications of fremanezumab's FDA labels, with every medicine labeled for each:
Source: FDA drug label (AJOVY), Teva Pharmaceuticals USA, Inc., effective June 5, 2026 (SPL set 98e344ea-5916-4947-b6f2-4a76ccc04b6b), via openFDA; the full label on DailyMed
Is there a generic for fremanezumab (Ajovy)?
No generic fremanezumab is approved (Drugs@FDA, October 8, 2026).
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for fremanezumab (Ajovy)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $508.17 per mL (Ajovy 225 mg/1.5 mL autoinject), up 5% from $483.00 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ajovy 225 mg/1.5 mL autoinject (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ajovy 225 mg/1.5 mL autoinject | Brand | $508.17 per mL | $762.26 per autoinj | +5% |
| Ajovy 225 mg/1.5 mL autoinjector (3 pack) | Brand | $507.45 per mL | $761.17 per autoinj | n/a |
| Ajovy 225 mg/1.5 mL syringe | Brand | $508.51 per mL | $762.76 per syringe | +5% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for fremanezumab?
The FDA Adverse Event Reporting System holds 11,413 reports that list fremanezumab among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 108 are coded as a death and 829 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as fremanezumab?
4 other medicines are given the same way (subcutaneous) and in the same FDA class as fremanezumab or labeled mainly for the same use (migraine), the same class first. Migraine lists all 27 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (subcutaneous) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Sumatriptan | Migraine | 20 labelers | $14.93 per mL 6 mg/0.5 mL vial | No current entry |
| Erenumab | Migraine | none listed | $753.33 per mL 140 mg/mL autoinjector | No current entry |
| Galcanezumab | Migraine | none listed | $734.28 per mL 120 mg/mL pen | No current entry |
| Dihydroergotamine | Migraine | none listed | n/a | No current entry |
Every medicine labeled for the same conditions as fremanezumab
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to fremanezumab
- 4 medicines for the same use
- Fremanezumab side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other